Galapagos NV (AMS:GLPG)
24.46
-0.14 (-0.57%)
Apr 16, 2026, 5:35 PM CET
Galapagos NV Revenue
In the year 2025, Galapagos NV had annual revenue of 1.11B EUR with 303.50% growth. Galapagos NV had revenue of 900.82M in the quarter ending December 31, 2025, with 1,093.22% growth.
Revenue
1.11B
Revenue Growth
+303.50%
P/S Ratio
1.46
Revenue / Employee
1.58M
Employees
558
Market Cap
1.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.11B | 836.60M | 303.50% |
| Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
| Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
| Dec 31, 2022 | 241.25M | 85.33M | 54.73% |
| Dec 31, 2017 | 155.92M | 4.31M | 2.84% |
| Dec 31, 2016 | 151.61M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Koninklijke BAM Groep nv | 7.04B |
| Signify | 5.77B |
| Havas | 2.91B |
| Fugro | 1.85B |
| AMG Critical Materials | 1.45B |
| Basic-Fit | 1.42B |
| Corbion | 1.27B |
| Flow Traders | 798.22M |
Galapagos NV News
- 16 days ago - Galapagos Enters Framework Agreement With Gilead In Connection With Ouro Deal - Nasdaq
- 16 days ago - Galapagos NV: Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - Finanz Nachrichten
- 16 days ago - Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - GlobeNewsWire
- 21 days ago - Galapagos NV: Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings - Finanz Nachrichten
- 21 days ago - Galapagos NV: Galapagos Announces Nomination of Gino Santini to its Board of Directors - Finanz Nachrichten
- 21 days ago - Galapagos Announces Nomination of Gino Santini to its Board of Directors - GlobeNewsWire
- 21 days ago - Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders' Meetings - GlobeNewsWire
- 24 days ago - Galapagos NV: Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - Finanz Nachrichten